Trials / Recruiting
RecruitingNCT06467461
Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This project will test the hypotheses that people with 5-HT RBD have systemic alpha- synuclein pathology, prodromal DLB signs, and brainstem lesions in regions that control REM sleep. AIM 1 will seek to detect abnormally phosphorylated alpha- synuclein aggregates on targeted skin biopsy in a cohort of people with 5-HT RBD and matched controls (taking SSRIs but without RBD). Aim 2 will use ultra-high field MRI at 7T to examine the pontine region of the coeruleus/subcoeruleus complex for evidence of neurodegeneration as well as segment and parcellate REM sleep related neuronal structures. Aim 3 will test for speech deficits. While these aims are independent we suspect that the severity of autonomic, speech and cognitive deficits will correlate with loss of neuromelanin signal on MRI and pathology on skin biopsy. The investigation is a longitudinal designed study to examine histopathology, neuroimaging changes and speech function from baseline (Time 1) to a follow-up after 30 months (Time 2). A total of 60 individuals, 30 with 5-HT RBD and 30 controls, will be recruited at Time 1, brought back at Time 2, and tested across all Aims at both study visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Skin biopsy | Skin biopsy to detect systemic alpha-synuclein pathology in 5-HT RBD |
| DIAGNOSTIC_TEST | Speech testing | Speech Testing to quantify evolving signs of 5-HT RBD |
| DIAGNOSTIC_TEST | Ultra high field 7T MRI | 7T MRI to examine 5-HT RBD for evidence of brainstem neurodegeneration |
Timeline
- Start date
- 2024-02-08
- Primary completion
- 2027-12-01
- Completion
- 2028-09-01
- First posted
- 2024-06-21
- Last updated
- 2025-07-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06467461. Inclusion in this directory is not an endorsement.